PhotoPharmics Secures $6M for Parkinson’s Light Therapy Trial

PhotoPharmics, a leader in specialized light therapy for neurodegenerative diseases, has closed its oversubscribed $6 million Series B extension, led by Kickstart Fund with participation from both current and new investors. This round reflects strong confidence in the company’s clinical promise and the commercial potential of its Parkinson’s therapy.

A clinical-stage medical device company, PhotoPharmics is pioneering next-generation light-based therapies for neurodegenerative diseases. With over three decades of experience in phototherapy research, the company’s founders previously developed circadian-regulating light solutions that are now widely used for conditions like seasonal affective disorder, sleep disturbances, anxiety, and depression, before being acquired by Philips-Respironics in 2007. Building on this expertise, the company is developing therapeutic applications of specialized light for neurodegenerative conditions, with its lead innovation, Celeste®, targeting Parkinson’s disease. Celeste delivers proprietary wavelengths and intensities of light through the eyes to activate neurological pathways, improving daily functioning in individuals with Parkinson’s without the systemic side effects of traditional pharmaceuticals.

Celeste is currently being evaluated in the Light for PD Phase 3 clinical trial, which has enrolled over 200 participants across the United States. Early results have shown significant improvements in both motor and non-motor symptoms, including mood, cognition, and sleep quality. The new funding will support the completion of this pivotal trial, aid in FDA research, strengthen strategic partnerships, and prepare for market launch.

“We’re grateful for the enthusiasm and support of our investors as we move toward the finish line of our clinical program,” said Kent Savage, CEO of PhotoPharmics. “This funding provides the runway we need to complete our FDA research, build strategic partnerships, and ensure the best possible outcomes for patients.”

With its novel, non-invasive approach, PhotoPharmics is committed to delivering clinically validated, safe, and effective treatments to improve the lives of patients with Parkinson’s and other neurodegenerative disorders.